In November last year, it was confirmed that there was no pre-application for Ultomiris and Soliris benefits for new patients with paroxysmal night hemoglobin (PNH). There were only two applications for pre-approval of Soliris and one application for re-examination approval for new patients with atypical hemolytic uremic syndrome (aHUS), all of which were rejected.

In the case of Spinraza, a treatment for Spinal Muscular Atrophy (SMA), two applications for new patient benefits have been approved. The HIRA conducted deliberation on 11 items, including ventricular adjuvant therapy (VAD), short-term hospitalization (2–4 days) with neuroblocking treatment, including Soliris and Ultomiris, short-term h